Clicky

Recce Ltd  (RCE)

Description: Recce Limited is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.


Keywords: Medicine Pharmaceutical Cancer Disease Drugs Antibiotics Chemotherapy Melanoma Leukemia Bacteria Bacteriology Tuberculosis Veterinary Medicine Sepsis Stomach Antimicrobial Resistance Evolutionary Biology Helicobacter Pylori Gonorrhea

Home Page: www.recce.com.au

RCE Technical Analysis

Aurora Place
Sydney, NSW 2000
Australia
Phone: 61 2 9256 2571


Officers

Name Title
Mr. James Hamilton-Bray Graham GAICD CEO, MD & Exec. Director
Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) Chief Scientific Director & Exec. Director
Dr. Justin Ward Principal Quality Chemist & Exec. Director
Mr. Arthur Kollaras Principal Engineer & Head of Manufacturing
Mr. Justin Reynolds Chief Financial Officer
Thomas Jarrett Operations Mang.
Mr. Daniel Astudillo B.A., B.Com., M.B.A. Head of Marketing
Ms. Maggie Niewidok Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 11.7701
Price-to-Sales TTM: 38.0985
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks